Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Tarcocimab for Diabetic Retinopathy
Recruiting1 awardPhase 3
Augusta, Georgia
This trial will show that tarcocimab 5 mg is better than a fake treatment for people with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.